TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36227781

Group type: EXPERIMENTAL
Intervention: Fecal Short Chain Fatty Acids (SCFAs)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acetate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Total SCFAs
Number of subjects: 64
Study: 36227828

Group type: EXPERIMENTAL
Intervention: Deep learning-based image registration method
Number of subjects: 118
Study: 36227839

Group type: EXPERIMENTAL
Intervention: Active and passive case finding for wound management study
Number of subjects: 3842

Group type: EXPERIMENTAL
Intervention: Buruli ulcer prevalence
Number of subjects: 3842
Study: 36227844

Group type: EXPERIMENTAL
Intervention: Community-based wound management (C)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Health centre wound management (HC)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: District hospital wound management (DH)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Acute wound management
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Chronic wound management
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Recapturing of wounds
Number of subjects: 561
Study: 36227860

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 0
Study: 36228064

Group type: EXPERIMENTAL
Intervention: Clock-drawing test (abnormal)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Clock-drawing test (normal)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (female, 8th grade education or less)
Number of subjects: 1448
Study: 36228060

Group type: EXPERIMENTAL
Intervention: More effective facilitators
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Less effective facilitators
Number of subjects: 1630
Study: 36228112

Group type: EXPERIMENTAL
Intervention: Topical bexarotene
Number of subjects: 0
Study: 36228130

Group type: EXPERIMENTAL
Intervention: DigiCOVID protocol (remote teletherapy sessions)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DigiCOVID protocol (8 teletherapy sessions)
Number of subjects: 122
Study: 36228643

Group type: EXPERIMENTAL
Intervention: UCART19
Number of subjects: 25
Study: 36228644

Group type: EXPERIMENTAL
Intervention: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy (30 Gy in 15 fractions for stage IIA and 36 Gy in 18 fractions for stage IIB)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy
Number of subjects: 116
Study: 36228700

Group type: EXPERIMENTAL
Intervention: Withdrawal time of 6 minutes
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Every 1-minute increase in withdrawal time
Number of subjects: 1142
Study: 36228746

Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and every 3-week cisplatin (arm 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and cetuximab (arm 3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nivolumab alone for platinum-ineligible patients (arm 4)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nivolumab (all arms)
Number of subjects: 39
Study: 36229024

Group type: EXPERIMENTAL
Intervention: Probiotics (Actiregularis, 5×10^6) added to the diet of mothers once daily for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 0
Study: 36229089

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - Low Dose (112 mg)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - Moderate Dose (342 mg)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - High Dose (379 mg)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - All doses
Number of subjects: 794
Study: 36229091

Group type: EXPERIMENTAL
Intervention: CHIP carriers
Number of subjects: 446

Group type: COMPARATOR
Intervention: Non-CHIP patients
Number of subjects: 446
Study: 36229153

Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations with automatic decision-making software for ejection fraction (autoEF)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations with automatic decision-making software for mitral annular plane systolic excursion (autoMAPSE)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations by novices
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations by experts
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Automatic measurements of autoEF and autoMAPSE
Number of subjects: 166
Study: 36229188

Group type: EXPERIMENTAL
Intervention: presymptomatic MS
Number of subjects: 177

Group type: COMPARATOR
Intervention: healthy controls (HCs)
Number of subjects: 177
Study: 36229329

Group type: EXPERIMENTAL
Intervention: CLES (Remote ex vivo lung perfusion)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (conventional static cold-preserved lungs)
Number of subjects: 115
Study: 36229547

Group type: EXPERIMENTAL
Intervention: TOGETHER-YA intervention
Number of subjects: 11
Study: 36229741

Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in T2DM patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Narrow diameter implants in normo-glycemic patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Narrow diameter implants (general)
Number of subjects: 31
Study: 36229790

Group type: EXPERIMENTAL
Intervention: Smart Triage digital triaging platform
Number of subjects: 15
Study: 36229853

Group type: EXPERIMENTAL
Intervention: DZD2269 (A2aR antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DZD2269 (A2aR antagonist) in combination with immune checkpoint inhibitors, radiotherapy, or chemotherapy
Number of subjects: 0
Study: 36230640

Group type: EXPERIMENTAL
Intervention: Intensified NILG-AML 01/00 protocol (high dose of ARAC plus idarubicin consolidation)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NPM1-mutated patients
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Isolated ITD patients
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NPM1-co-mutated patients with ITD or TKD mutation
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NPM1 wild-type and FLT3-mutated patients
Number of subjects: 171
Study: 36230669

Group type: EXPERIMENTAL
Intervention: Oral swab assessment before RT
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Tumour site and lymphocytopenia as risk factors
Number of subjects: 152
Study: 36231265

Group type: COMPARATOR
Intervention: NHF data
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHA2DS2VASc score from NHF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc score from IHR
Number of subjects: 0
Study: 36231487

Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins A, E, D) and microelements (Cu, Se, Zn) levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Copper (Cu) levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Copper (Cu) and Zinc (Zn) levels
Number of subjects: 80
Study: 36231670

Group type: EXPERIMENTAL
Intervention: Decreased physical activity (58% women, 55% men at the beginning; 56% women, 53% men at the end)
Number of subjects: 32409

Group type: EXPERIMENTAL
Intervention: Increased physical activity (20% women, 14% men at the beginning; 23% women, 18% men at the end)
Number of subjects: 32409

Group type: EXPERIMENTAL
Intervention: Reasons for decreased physical activity
Number of subjects: 32409

Group type: EXPERIMENTAL
Intervention: Reasons for increased physical activity
Number of subjects: 32409

Group type: EXPERIMENTAL
Intervention: Physical activity changes
Number of subjects: 32409
Study: 36231682

Group type: EXPERIMENTAL
Intervention: Tonometry data analysis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Various techniques (analysis of variance, network correlation structure analysis, multinomial logistic regression, discrimination analysis)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Feature selection methods
Number of subjects: 6
Study: 36231712

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent training (MCT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual lifestyle (Control group)
Number of subjects: 106
Study: 36231817

Group type: EXPERIMENTAL
Intervention: Flexible Cognitive Restraint Scale
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Rigid Cognitive Restraint Scale
Number of subjects: 620
Study: 36232227

Group type: EXPERIMENTAL
Intervention: Support system and resilience
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Higher resilience and support system
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Family distress
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Perceived university support
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Preferred sources of support
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: University support services
Number of subjects: 1121
Study: 36233712

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (6 weekly sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study: 36233717

Group type: EXPERIMENTAL
Intervention: Induced hypertension
Number of subjects: 303

Group type: COMPARATOR
Intervention: Invasive endovascular treatment
Number of subjects: 303
Study: 36235639

Group type: EXPERIMENTAL
Intervention: Mixed sources containing sugar-sweetened beverages (SSBs)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fruit, 100% fruit juice, sweetened soy beverage, dark chocolate
Number of subjects: 64
Study: 36237146

Group type: EXPERIMENTAL
Intervention: NINDS-CSN cognitive battery (executive functioning, attention, processing speed)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 110
Study: 36237618

Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 36237908

Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent (DES)
Number of subjects: 178
Study: 36237914

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2-i)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Non-SGLT2 inhibitors (control group)
Number of subjects: 646
Study: 36238450

Group type: EXPERIMENTAL
Intervention: IOE supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36238465

Group type: EXPERIMENTAL
Intervention: Maternal-infant biological samples (blood, feces, saliva, urine, and breast milk) collected during pregnancy and the first year of life.
Number of subjects: 0
Study: 36238568

Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study: 36238712

Group type: EXPERIMENTAL
Intervention: mHealth tool (MoVeUP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard approach)
Number of subjects: 0
Study: 36238717

Group type: EXPERIMENTAL
Intervention: mRNA-1283
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 0
Study: 36239199

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 15 mg t.i.d.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaler 20 µg 2 puffs t.i.d.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 30 mg of honey t.i.d.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study: 36239473

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 mg/m2 on day 1 combined with ifosfamide (IFO) 1.8 g/m2 on days 1-5 every 21 days for up to six cycles
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exploratory biomarker analysis
Number of subjects: 69
Study: 36239625

Group type: EXPERIMENTAL
Intervention: TORS
Number of subjects: 44

Group type: COMPARATOR
Intervention: RT
Number of subjects: 44
Study: 36239788

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 937

Group type: COMPARATOR
Intervention: No chemotherapy (Control)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Chemotherapy and No chemotherapy
Number of subjects: 937
Study: 36239858

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) therapy (200 kHz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physicians' choice standard-of-care (PC-SOC)
Number of subjects: 0
Study: 36239955

Group type: EXPERIMENTAL
Intervention: Email reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized telephone outreach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of both email reminders and personalized telephone outreach
Number of subjects: 0
Study: 36240004

Group type: EXPERIMENTAL
Intervention: mHealth intervention (InCharge Health app)
Number of subjects: 55
Study: 36240084

Group type: EXPERIMENTAL
Intervention: Idiopathic Intracranial Hypertension (IIH) participants undergoing weight loss intervention for disease remission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sex-matched, age-matched, and BMI-matched)
Number of subjects: 0
Study: 36240089

Group type: EXPERIMENTAL
Intervention: Cognitive IADL impairment (n = 37) at baseline
Number of subjects: 268

Group type: COMPARATOR
Intervention: PD-MCI
Number of subjects: 268

Group type: COMPARATOR
Intervention: No cognitive impairment
Number of subjects: 268

Group type: COMPARATOR
Intervention: Dementia
Number of subjects: 268
Study: 36240181

Group type: EXPERIMENTAL
Intervention: Complicated acute appendicitis
Number of subjects: 118

Group type: COMPARATOR
Intervention: Uncomplicated acute appendicitis
Number of subjects: 118
Study: 36240296

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT in patients with graft rejection (12%, N = 20)
Number of subjects: 163
Study: 36240323

Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate (βOHB) infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 36240452

Group type: EXPERIMENTAL
Intervention: GROW intervention (online parenting-skills program with six online learning modules and videoconference meetings with a coach)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GROW intervention
Number of subjects: 72
Study: 36240755

Group type: EXPERIMENTAL
Intervention: Fourth dose of BNT162b2 vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: B cell-depleting therapies within 12 months before vaccination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breakthrough infections after vaccination
Number of subjects: 80
Study: 36241629

Group type: EXPERIMENTAL
Intervention: Certolizumab plus cisplatin and pemetrexed
Number of subjects: 18
Study: 36241696

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and DHAP
Number of subjects: 65
Study: 36241843

Group type: EXPERIMENTAL
Intervention: cSAH patients with suspected CAA
Number of subjects: 50
Study: 36241982

Group type: EXPERIMENTAL
Intervention: 0.5 ml subcutaneous injection of SPIO with 30-s massage
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.0 ml intracutaneous injection of SPIO with 2-min massage
Number of subjects: 6
Study: 36242017

Group type: EXPERIMENTAL
Intervention: Regular reading activities
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Higher education levels (more than 13 years)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: More reading activities in low education groups (less than 12 years)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Non-reading group
Number of subjects: 459
Study: 36242033

Group type: EXPERIMENTAL
Intervention: Overall high HrQoL (47% of sample)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Progressively decreasing HrQoL (32%)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall low HrQoL (8%)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Asymmetric decline in HrQoL (13%)
Number of subjects: 600
Study: 36242576

Group type: EXPERIMENTAL
Intervention: EF-D group
Number of subjects: 57

Group type: COMPARATOR
Intervention: EF-N group
Number of subjects: 57
Study: 36242633

Group type: EXPERIMENTAL
Intervention: High angiogenic habitat
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermediate angiogenic habitat
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Relative cerebral blood volume (rCBV)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vascular habitats combining high and intermediate angiogenic habitats
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vascular habitats stratification
Number of subjects: 69
Study: 36242680

Group type: EXPERIMENTAL
Intervention: Redo Bariatric Surgery (RBS)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB) as RBS
Number of subjects: 529
Study: 36242700

Group type: EXPERIMENTAL
Intervention: metastasis-directed therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: intensified hormonal treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: modern imaging (e.g. PSMA PET/CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ablative local treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: newest systemic therapies
Number of subjects: 0
Study: 36242742

Group type: EXPERIMENTAL
Intervention: Debridement, antibiotics and implant retention (DAIR) with rifampicin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prosthesis removal
Number of subjects: 120

Group type: COMPARATOR
Intervention: Debridement, antibiotics and implant retention (DAIR) without rifampicin
Number of subjects: 120
Study: 36242744

Group type: EXPERIMENTAL
Intervention: Relative abundance of Akkermansia, Lachnospiraceae sp. and Ruminococcus genera
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Relative abundance of Bifidobacterium genus
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Relative abundance of Sutterellaceae and Bifidobacteriaceae families
Number of subjects: 82
Study: 36242764

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study: 36243061

Group type: EXPERIMENTAL
Intervention: Telemedicine multidisciplinary ICU recovery clinic visits
Number of subjects: 32
Study: 36243111

Group type: EXPERIMENTAL
Intervention: hs-cTnI-EXL
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: hs-cTnI-Architect
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: hs-cTnT-Elecsys
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: hs-cTnI-EXL-specific 0/1h-algorithm
Number of subjects: 1454
Study: 36243199

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 36243263

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) monitoring of micro-embolic signals (MES) pre- and post-carotid endarterectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of plaque characteristics
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Histopathological analysis of plaque vulnerability
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stenosis severity assessment
Number of subjects: 120
Study: 36243733

Group type: EXPERIMENTAL
Intervention: High serum Humanin (HN) levels
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: High serum GDF15 levels
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: High serum FGF21 levels
Number of subjects: 165
Study: 36243744

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) measured at V1, V2, V3, and V5
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Area under the curve of HMOs from baseline to 4 months of age
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not applicable (no control group)
Number of subjects: 41
Study: 36243812

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg (UPA15)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (UPA30)
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Adalimumab 40 mg (ADA)
Number of subjects: 1704
Study: 36244405

Group type: EXPERIMENTAL
Intervention: Excessive QTVi during arousal
Number of subjects: 2558
Study: 36244653

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 36244863

Group type: EXPERIMENTAL
Intervention: BKL angiographic pattern
Number of subjects: 389

Group type: COMPARATOR
Intervention: Non-BKL angiographic pattern (Control)
Number of subjects: 389
Study: 36244985

Group type: EXPERIMENTAL
Intervention: Neck Disability Index (NDI-G)
Number of subjects: 50
Study: 36245008

Group type: EXPERIMENTAL
Intervention: IHSG wording
Number of subjects: 1430

Group type: COMPARATOR
Intervention: PP wording
Number of subjects: 1430
Study: 36245627

Group type: EXPERIMENTAL
Intervention: Aggressive warming to a target core temperature of 37 ℃
Number of subjects: 205

Group type: COMPARATOR
Intervention: Routine thermal management to a target of 35.5 ℃
Number of subjects: 205
Study: 36245729

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement (≥100 μg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement (<100 μg/g)
Number of subjects: 0
Study: 36245743

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey-based follow-on formula (pHF-W FoF)
Number of subjects: 100
Study: 36246184

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg fixed dosing every 8 weeks after initial treatment with 6 intravitreal doses at 4-week intervals
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg dosed according to personalized treatment interval (PTI) after initial treatment with 4 every-4-week doses
Number of subjects: 1891

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg dosed every 8 weeks after 5 initial every-4-week doses
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg with PTI regimen (up to every-16-week adjustable dosing)
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg and Aflibercept 2.0 mg
Number of subjects: 1891
Study: 36246814

Group type: EXPERIMENTAL
Intervention: 0.5 mg/d ETV (Group A)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: ETV maleate (Group B)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 275